BAY Z 4305
Latest Information Update: 09 Jul 2002
At a glance
- Originator Bayer
- Class Antiretrovirals
- Mechanism of Action RNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 21 Jun 1999 BAY Z 4305 is available for licensing (http://www.bayer.com)
- 21 Jun 1999 New profile
- 21 Jun 1999 Preclinical development for HIV-1 infections in Germany (Unknown route)